Fcpm Iii Services B.V. Sells 895,781 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Fcpm Iii Services B.V. decreased its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 18.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,970,668 shares of the company's stock after selling 895,781 shares during the quarter. Replimune Group makes up 8.2% of Fcpm Iii Services B.V.'s portfolio, making the stock its 5th biggest position. Fcpm Iii Services B.V. owned 5.80% of Replimune Group worth $48,085,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Boxer Capital Management LLC acquired a new stake in Replimune Group during the fourth quarter valued at approximately $21,754,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Replimune Group by 11.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after purchasing an additional 1,083,633 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Replimune Group during the fourth quarter valued at approximately $10,853,000. Wellington Management Group LLP grew its holdings in Replimune Group by 352.5% in the 4th quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock worth $13,282,000 after buying an additional 854,346 shares in the last quarter. Finally, Artisan Partners Limited Partnership acquired a new stake in Replimune Group in the fourth quarter worth approximately $7,399,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Stock Up 1.9%

Shares of NASDAQ:REPL traded up $0.15 during midday trading on Monday, hitting $7.86. 764,794 shares of the stock were exchanged, compared to its average volume of 898,815. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The company has a market capitalization of $605.34 million, a PE ratio of -2.56 and a beta of 0.68. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The business's fifty day simple moving average is $9.36 and its two-hundred day simple moving average is $11.48.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, research analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on REPL shares. BMO Capital Markets raised their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. HC Wainwright increased their target price on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. increased their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.